These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Brazil: An emerging partner in drug R&D. Rodrigues DG IDrugs; 2009 Aug; 12(8):497-502. PubMed ID: 19629884 [TBL] [Abstract][Full Text] [Related]
5. Pfizer and its competitive marketing challenges. Carter T J Hosp Mark Public Relations; 2003; 14(2):85-97. PubMed ID: 14753324 [TBL] [Abstract][Full Text] [Related]
6. When medicine becomes a disease. Arabia; 1986 Mar; 5(55):32-6. PubMed ID: 12340711 [TBL] [Abstract][Full Text] [Related]
7. Defensive marketing: how a strong incumbent can protect its position. Roberts JH Harv Bus Rev; 2005 Nov; 83(11):150-2, 154, 156-7 passim. PubMed ID: 16299967 [TBL] [Abstract][Full Text] [Related]
8. Generics market in Greece: the pharmaceutical industry's beliefs. Geitona M; Zavras D; Hatzikou M; Kyriopoulos J Health Policy; 2006 Nov; 79(1):35-48. PubMed ID: 16386326 [TBL] [Abstract][Full Text] [Related]
9. Mastering the value chain. An interview with Mark Levin of Millennium Pharmaceuticals. Interview by David Champion. Levin M Harv Bus Rev; 2001 Jun; 79(6):108-15, 148. PubMed ID: 11408971 [TBL] [Abstract][Full Text] [Related]
10. Gray marketing of pharmaceuticals. Chaudhry PE; Walsh MG J Health Care Mark; 1995; 15(3):18-22. PubMed ID: 10172516 [TBL] [Abstract][Full Text] [Related]
11. Competing with giants. Survival strategies for local companies in emerging markets. Dawar N; Frost T Harv Bus Rev; 1999; 77(2):119-29, 187. PubMed ID: 10387768 [TBL] [Abstract][Full Text] [Related]
12. Is your company ready for one-to-one marketing? Peppers D; Rogers M; Dorf B Harv Bus Rev; 1999; 77(1):151-60. PubMed ID: 10345390 [TBL] [Abstract][Full Text] [Related]
13. Global marketing of cholesterol-lowering drugs as therapy. Elimimian JU; Gilmore JM; Singletary TJ J Hosp Mark Public Relations; 2006; 16(1-2):15-28. PubMed ID: 17194684 [TBL] [Abstract][Full Text] [Related]
15. Sale strategies of pharmaceutical companies in a "pharmerging" country: the problems will not improve if the gaps remain. Civaner M Health Policy; 2012 Aug; 106(3):225-32. PubMed ID: 22682762 [TBL] [Abstract][Full Text] [Related]
16. Effective executive management in the pharmaceutical industry. Tran H; Kleiner BH J Health Care Finance; 2005; 32(1):8-15. PubMed ID: 18972973 [TBL] [Abstract][Full Text] [Related]
17. The globalisation strategies of five Asian tobacco companies: a comparative analysis and implications for global health governance. Lee K; Eckhardt J Glob Public Health; 2017 Mar; 12(3):367-379. PubMed ID: 28139967 [TBL] [Abstract][Full Text] [Related]
18. Japan-China merger puts growth in East Asia first. Sipp D Nat Biotechnol; 2005 Aug; 23(8):907. PubMed ID: 16082348 [No Abstract] [Full Text] [Related]
19. Strategies to fight low-cost rivals. Kumar N Harv Bus Rev; 2006 Dec; 84(12):104-12, 163. PubMed ID: 17183797 [TBL] [Abstract][Full Text] [Related]
20. Category Captain Management: a new approach for healthcare suppliers to partner with their hospital customers. Trombetta B J Hosp Mark Public Relations; 2007; 17(2):61-9. PubMed ID: 18072705 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]